Episode 83: Retinopathy of Prematurity: Has Anti-VEGF Changed the Game?

Anti-VEGF has transformed how we treat retinopathy of prematurity — but at what long-term cost? Dr Kanmin Xue chairs a global discussion with Dr Domenico Lepore, Prof Wei-Chi Wu and Prof Andreas Stahl on injections versus laser, the RAINBOW and FIREFLEYE trial data, managing peripheral avascular retina, and why these babies may need follow-up for life. A frank look at the questions the evidence hasn't yet answered.